Victory Capital Management Inc Salarius Pharmaceuticals, Inc. Transaction History

Victory Capital Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 07, 2020	SELL	$0.6 - $1.82 $1,182 - $3,587	-1,971 Closed	0 $0
Q1 2020 May 04, 2020	BUY	$0.56 - $3.82 $1,048 - $7,151	1,872 Added 1890.91%	1,971 $1,000
Q4 2019 Feb 06, 2020	SELL	$3.02 - $5.9 $1,582 - $3,091	-524 Reduced 84.11%	99 $1,000
Q4 2019 Feb 04, 2020	BUY	$3.02 - $5.9 $1,582 - $3,091	524 Added 529.29%	623 $2,000
Q3 2019 Nov 12, 2019	BUY	$5.28 - $20.25 $522 - $2,004	99 New	99 $1,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $3.16M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.